|
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
RECRUITINGPhase 2Sponsored by Shanghai Zhongshan Hospital
Actively Recruiting
PhasePhase 2
SponsorShanghai Zhongshan Hospital
Started2025-06-20
Est. completion2027-03-31
Eligibility
Age70 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07012980
Summary
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Eligibility
Age: 70 Years+Healthy volunteers accepted
Inclusion Criteria:
Subjects will only be included in the study if they meet all the following criteria:
1. Written informed consent.
2. Aged 70 years old or above.
3. ECOG performance status of 0-3.
4. Histologically confirmed CD20 positive DLBCL.
5. At least one measurable site of disease.
6. Patient did not receive any prior lymphoma therapy.
7. Patient has a life expectancy (in the opinion of the investigator) of at least 12 weeks.
8. Patient has adequate liver function:
* Total bilirubin ≤1.5 x ULN (≤3 x ULN in patients with Gilbert's syndrome).
* AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤3 x ULN. o Patients with documented liver involvement: AST and/or ALT ≤5 x ULN.
9. Patient as adequate hematological function, unless due to lymphoma:
* Hemoglobin ≥9.0 g/dL within 7 days before the first treatment.
* Absolute neutrophil count of ≥1.0 x 109 cells/L (1,000/μL).
* Platelet count of ≥75 x 109 cells/L (75,000/μL). Note: Transfusion of RBCs and platelets is allowed to reach the inclusion criteria. In case screening procedures are leading to situations that would exclude the patient from study participation (such as Hb value below entry criteria), the patient may still be enrolled into the trial after consultation with the principal investigator.
10. Patient has adequate renal function:
* Creatinine ≤ 1.5 x ULN, or
* Creatinine clearance (CrCl) calculated by Cockcroft-Gault formula of ≥ 30 mL/min for patients in whom, in the Investigator's judgment, serum creatinine levels do not adequately reflect renal function.
Exclusion Criteria:
Subjects will not be included in the study if any of the following criteria apply:
1. History of severe cardiac disease: New York Heart Association (NYHA) grade 3-4, congestive heart failure, myocardial infarction or cerebrovascular accident within the past 3 months, unstable arrhythmias, or unstable angina or history of multiple cardiovascular events) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
Note: Congestive heart failure NYHA II patients can be included if they provide an LVEF \>40%.;
2. Patient with current or history of CNS lymphoma.
3. Patient with uncontrolled severe infection, whether bacterial (e.g., tuberculosis), viral (including, but not limited to severe pneumonia, COVID-19, Epstein-Barr virus \[EBV\], cytomegalovirus \[CMV\], hepatitis B, hepatitis C, and HIV\], fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks prior to study enrollment.
Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
4. Patient with current \> Grade 1 peripheral neuropathy.
5. Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment
6. Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study.
7. Known hypersensitivity to Chinese hamster ovary (CHO) cell products or to any component of the zanubrutinib, polatuzumab vedotin, obinutuzumab, or glofitamab and/or to the contrast agents used in the study.
\-Conditions2
CancerDiffuse Large B-Cell Lymphoma
Interventions3
Related trials
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. — Australasian Leukaemia and Lymphoma Group
- An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas — National Research Center for Hematology, Russia
- Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) — University Health Network, Toronto
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma — Peking University Third Hospital
- Glofitamab in Chinese Patients With R/R DLBCL — Peking Union Medical College Hospital
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) — Ryvu Therapeutics SA
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma — The Lymphoma Academic Research Organisation
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorShanghai Zhongshan Hospital
Started2025-06-20
Est. completion2027-03-31
Eligibility
Age70 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07012980